Faes Farma SA banner
F

Faes Farma SA
MAD:FAE

Watchlist Manager
Faes Farma SA
MAD:FAE
Watchlist
Price: 5.38 EUR 1.51% Market Closed
Market Cap: €1.7B

Gross Margin

65.1%
Current
Declining
by 0.7%
vs 3-y average of 65.8%

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
65.1%
=
Gross Profit
€370.1m
/
Revenue
€568.1m

Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.

Gross Margin
65.1%
=
Gross Profit
€370.1m
/
Revenue
€568.1m

Peer Comparison

Country Company Market Cap Gross
Margin
ES
Faes Farma SA
MAD:FAE
1.7B EUR
Loading...
US
Eli Lilly and Co
NYSE:LLY
993.1B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
587B USD
Loading...
CH
Roche Holding AG
SIX:ROG
286.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
235.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
239B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
304.3B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
158.1B USD
Loading...
US
Bristol-Myers Squibb Co
NYSE:BMY
123.7B USD
Loading...

Market Distribution

Higher than 70% of companies in Spain
Percentile
70th
Based on 599 companies
70th percentile
65.1%
Low
-178.8% — 38.9%
Typical Range
38.9% — 65.1%
High
65.1% — 192.7%
Distribution Statistics
Spain
Min -178.8%
30th Percentile 38.9%
Median 52.5%
70th Percentile 65.1%
Max 192.7%

Faes Farma SA
Glance View

Faes Farma SA, a notable player in the pharmaceutical arena, has orchestrated its operations with the precision of a seasoned conductor. Rooted in Spain with an impressive international reach, the company blends research prowess with adept production capabilities. Central to its modus operandi is the development, manufacture, and commercialization of a wide range of pharmaceutical products and nutritional supplements. With science as its guiding star, Faes Farma dedicates substantial resources to research and development, ensuring a pipeline filled with innovative treatments that cater to diverse medical needs. The company has carved its niche by focusing on therapeutic areas such as allergy, dermatology, and the central nervous system, allowing it to create specialized solutions that resonate well with healthcare providers and patients alike. The company’s revenue engine is driven primarily by its robust product sales, enhanced by strategic partnerships and licensing agreements that bolster its market presence both in Spain and across global markets. Through rigorous production processes, Faes Farma ensures the delivery of high-quality medications, matching industry standards and fostering consumer trust. Additionally, its geographical diversification, with subsidiaries and distribution channels spreading across Europe, Latin America, and Africa, underpins its economic durability. By marrying innovation with strategic commercial tactics, Faes Farma has deftly navigated the complexities of the pharmaceutical landscape, ensuring not only profitability but also the sustained delivery of health-enhancing products to the global community.

FAE Intrinsic Value
HIDDEN
Show
What is Gross Margin?
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
How is Gross Margin calculated?

Gross Margin is calculated by dividing the Gross Profit by the Revenue.

Gross Margin
65.1%
=
Gross Profit
€370.1m
/
Revenue
€568.1m
What is Faes Farma SA's current Gross Margin?

The current Gross Margin for Faes Farma SA is 65.1%, which is below its 3-year median of 65.8%.

How has Gross Margin changed over time?

Over the last 3 years, Faes Farma SA’s Gross Margin has increased from 63.3% to 65.1%. During this period, it reached a low of 63.3% on Sep 30, 2022 and a high of 66.5% on Jun 30, 2024.

Back to Top